UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 236

Sortiert nach

Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

Clinical and translational science, 2022-05, Vol.15 (5), p.1131-1142

2022

Volltextzugriff (PDF)

Neoadjuvant Enzalutamide Prior to Prostatectomy

Clinical cancer research, 2017-05, Vol.23 (9), p.2169-2176

2017

Volltextzugriff (PDF)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

BMJ open, 2021-08, Vol.11 (8), p.e046588-e046588

2021

Volltextzugriff (PDF)

Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues

World journal of surgery, 2006-04, Vol.30 (4), p.628-636

2006

Volltextzugriff (PDF)

A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy

The Journal of urology, 2015-04, Vol.193 (4), p.1305-1310

2015

Volltextzugriff (PDF)

Association of MnSOD AA Genotype with the Progression of Prostate Cancer

PloS one, 2015-07, Vol.10 (7), p.e0131325-e0131325

2015

Volltextzugriff (PDF)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Journal of clinical oncology, 2022-05, Vol.40 (15), p.1616-1622

2022

Volltextzugriff (PDF)

An update on enzalutamide in the treatment of prostate cancer

Therapeutic Advances in Urology, 2015-02, Vol.7 (1), p.9-21

2015

Volltextzugriff (PDF)

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy

Urologic oncology, 2015-06, Vol.33 (6), p.269-269

2015

Volltextzugriff (PDF)

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

The New England journal of medicine, 2023-10, Vol.389 (16), p.1453-1465

2023

Volltextzugriff (PDF)

Saturation biopsies for prostate cancer: current uses and future prospects

Nature reviews. Urology, 2009-12, Vol.6 (12), p.645-652

2009

Volltextzugriff (PDF)

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

The Journal of urology, 2021-05, Vol.205 (5), p.1361-1371

2021

Volltextzugriff (PDF)

A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval

Urologic oncology, 2015-03, Vol.33 (3), p.115-115

2015

Volltextzugriff (PDF)

The spectrum of eosinophilic cystitis in males: case series and literature review

Archives of pathology & laboratory medicine (1976), 2009-02, Vol.133 (2), p.289-294

2009

Volltextzugriff (PDF)

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

European urology, 2023-08, Vol.84 (2), p.229-241

2023

Volltextzugriff (PDF)

Temporal trends and racial disparities in global prostate cancer prevalence

Canadian journal of urology, 2014-10, Vol.21 (5), p.7496

2014

Volltextzugriff (PDF)

The worldwide epidemiology of prostate cancer: perspectives from autopsy studies

Canadian journal of urology, 2008-02, Vol.15 (1), p.3866

2008

Volltextzugriff (PDF)

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

European urology, 2015-02, Vol.67 (2), p.223-230

2015

Volltextzugriff (PDF)

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

Prostate cancer and prostatic diseases, 2022-02, Vol.25 (2), p.274-282

2022

Volltextzugriff (PDF)

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

The Prostate, 2022-09, Vol.82 (13), p.1237-1247

2022

Volltextzugriff (PDF)

Evaluation of Prostatitis in Autopsied Prostates—Is Chronic Inflammation More Associated With Benign Prostatic Hyperplasia or Cancer?

The Journal of urology, 2008-05, Vol.179 (5), p.1736-1740

2008

Volltextzugriff (PDF)

Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence

JNCI : Journal of the National Cancer Institute, 2007-10, Vol.99 (19), p.1484-1489

2007

Volltextzugriff (PDF)

MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status

In vivo (Athens), 2009-01, Vol.23 (1), p.7-12

2009

Volltextzugriff (PDF)

Is Penile Preservation of Distal Corporal Invasive Penile Cancer Sufficient Treatment?

The Journal of urology, 2013-09, Vol.190 (3), p.840-842

2013

Volltextzugriff (PDF)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Prostate cancer and prostatic diseases, 2022-02, Vol.25 (2), p.363-365

2022

Volltextzugriff (PDF)

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(236)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

Neoadjuvant Enzalutamide Prior to Prostatectomy

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues

A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy

Association of MnSOD AA Genotype with the Progression of Prostate Cancer

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

An update on enzalutamide in the treatment of prostate cancer

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

Saturation biopsies for prostate cancer: current uses and future prospects

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval

The spectrum of eosinophilic cystitis in males: case series and literature review

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

Temporal trends and racial disparities in global prostate cancer prevalence

The worldwide epidemiology of prostate cancer: perspectives from autopsy studies

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

Evaluation of Prostatitis in Autopsied Prostates—Is Chronic Inflammation More Associated With Benign Prostatic Hyperplasia or Cancer?

Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence

MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status

Is Penile Preservation of Distal Corporal Invasive Penile Cancer Sufficient Treatment?

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Suchergebnisse filtern